Search results for "PEPTIDE"

showing 10 items of 4589 documents

Creatinine and NT-ProBNP levels could predict the length of hospital stay of patients with decompensated heart failure.

2021

Heart failure (HF) is a clinical syndrome that causes high morbidity and mortality with a high number of admissions and sometimes prolonged admissions. This study aimed at assessing whether parameters detected during the first 24 h of admission may predict a prolonged hospital stay in patients admitted to hospital for decompensated HF.From January 2016 to December 2019, 2359 admissions of decompensated HF were recorded. In-hospital transfers,Univariate differences were found at admission in NT-ProBNP, creatinine, history of cardiac surgery, smoking and alcoholism, left and right ventricular ejection fraction, systolic blood pressure and heart rate. The ROC analysis showed significant areas …

medicine.medical_specialty030204 cardiovascular system & hematology03 medical and health scienceschemistry.chemical_compoundHigh morbidity0302 clinical medicineNatriuretic Peptide BrainmedicineHumansDecompensation030212 general & internal medicineClinical syndromeHeart FailureCreatininebusiness.industryStroke VolumeGeneral MedicineLength of Staymedicine.diseasePeptide FragmentschemistryHeart failureCreatinineEmergency medicineVentricular Function RightCardiology and Cardiovascular MedicinebusinessHospital stayActa cardiologica
researchProduct

Does the renin-angiotensin system also regulate intra-ocular pressure?

2009

The renin-angiotensin-aldosterone system is known to play an essential role in controlling sodium balance and body fluid volumes, and thus blood pressure. In addition to the circulating system which regulates urgent cardiovascular responses, a tissue-localized renin-angiotensin system (RAS) regulates long-term changes in various organs. Many recognized RAS components have also been identified in the human eye. The highly vasoconstrictive angiotensin II (Ang II) is considered the key peptide in the circulatory RAS. However, the ultimate effect of RAS activation at tissue level is more complex, being based not only on the biological activity of Ang II but also on the activities of other produ…

medicine.medical_specialty030204 cardiovascular system & hematologyPeptide hormoneRenin-Angiotensin System03 medical and health sciences0302 clinical medicineInternal medicineRenin–angiotensin systemMedicineAnimalsHumansIntraocular Pressurebiologybusiness.industryAngiotensin-converting enzymeBiological activityGeneral MedicineWater-Electrolyte BalanceAngiotensin IIBiosynthetic PathwaysBlood pressureEndocrinologyACE inhibitorCirculatory system030221 ophthalmology & optometrybiology.proteinOcular Hypertensionbusinessmedicine.drugAnnals of medicine
researchProduct

Is diabetes the cost to pay for a greater cardiovascular prevention?

2010

The recent JUPITER (Justification for the Use of statins in Primary prevention: an Intervention Trial Evaluating Rosuvastatin) trial is another study providing evidence about the effectiveness of statin therapy in reducing cardiovascular risk. Yet, in this study significantly higher glycated hemoglobin levels and incidence rates of diabetes were observed in persons treated with rosuvastatin than the placebo group. It should be noted that adverse effects on glucose metabolism have already been reported, albeit rarely, in previous trials with statins. Although the exact mechanisms involved are unknown, it seems that statins may deteriorate glycemic control by decreasing different metabolites,…

medicine.medical_specialty10265 Clinic for Endocrinology and Diabetology610 Medicine & healthDiabete2705 Cardiology and Cardiovascular Medicinechemistry.chemical_compoundDiabetes mellitusInternal medicinemedicineDiabetes MellitusHumansRosuvastatinRisk factorRosuvastatin CalciumAdverse effectGlycemicSulfonamidesbusiness.industryPreventionIncidence (epidemiology)Statinsnutritional and metabolic diseasesCardiovascular riskmedicine.diseaseFluorobenzenesRosuvastatin CalciumEndocrinologyPyrimidineschemistryCardiovascular DiseasesAtherosclerosilipids (amino acids peptides and proteins)Glycated hemoglobinHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular Medicinebusinessmedicine.drug
researchProduct

The effects of ezetimibe on LDL-cholesterol: quantitative or qualitative changes ?

2009

Ezetimibe represents the first of a new class of agents, the cholesterol absorption inhibitors, able to reduce low-density lipoproteins (LDL)-cholesterol by 15-25% from baseline in monotherapy and on top of statins and fibrates. To-date all the data regarding the efficacy of ezetimibe comes from the studies of its lipid-lowering power. Yet, recent findings from the ENHANCE study on atherosclerosis progression showed that the addition of ezetimibe to simvastatin in patients with heterozygous familial hypercholesterolemia did not affect the mean change in carotid intima-media thickness, although a significant reduction in LDL-cholesterol levels was present. Therefore, we cannot exclude that e…

medicine.medical_specialty10265 Clinic for Endocrinology and Diabetology610 Medicine & healthFamilial hypercholesterolemiaBioinformatics2705 Cardiology and Cardiovascular Medicinechemistry.chemical_compoundEzetimibePredictive Value of TestsInternal medicinemedicineAnimalsHumansProspective cohort studyCardiovascular risk Cholesterol LDL size Small dense LDLDyslipidemiasEzetimibe LDL-cholesterolCholesterolVascular diseasebusiness.industryAnticholesteremic AgentsHypertriglyceridemiaReproducibility of ResultsCholesterol LDLEzetimibemedicine.diseaseTreatment OutcomeEndocrinologychemistrySimvastatinAzetidinesDrug Therapy Combinationlipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessBiomarkersDyslipidemiamedicine.drug
researchProduct

The differential effects of thiazolidindiones on atherogenic dyslipidemia in type 2 diabetes: what is the clinical significance?

2008

Diabetic dyslipidemia is typically characterized by an increase in plasma triglycerides, a decrease in high-density lipoprotein cholesterol and a concomitant increase in atherogenic small dense low-density lipoproteins. Thiazolidindiones are able to lower the levels of fasting glucose and glycated hemoglobin significantly by improving insulin sensitivity, as well as improving some aspects of diabetic dyslipidemia: total cholesterol, low-density lipoprotein cholesterol and high-density lipoprotein cholesterol tend to increase while triglycerides are generally decreased.This paper reviewed the effects of pioglitazone and rosiglitazone on atherogenic diabetic dyslipidemia, in particular on sma…

medicine.medical_specialty10265 Clinic for Endocrinology and Diabetology610 Medicine & healthType 2 diabetesRosiglitazonechemistry.chemical_compoundDiabetes mellitusInternal medicinemedicine2736 Pharmacology (medical)HumansHypoglycemic AgentsPharmacology (medical)Clinical significancecardiovascular risk dense low-density lipoprotein diabetes low-density lipoprotein size pioglitazone rosiglitazone smallTriglyceridesDyslipidemiasPharmacologyAtherogenic dyslipidemiaPioglitazonebusiness.industryThiazolidindionesAtherogenic dyslipidemiaGeneral Medicinemedicine.diseaseLipoproteins LDLEndocrinology3004 PharmacologychemistryDiabetes Mellitus Type 2lipids (amino acids peptides and proteins)ThiazolidinedionesGlycated hemoglobinbusinessRosiglitazoneLipoproteins HDLPioglitazoneBiomarkersmedicine.drugLipoprotein
researchProduct

Prevalence estimation of celiac disease in the general adult population of Latvia using serology and HLA genotyping

2015

Background: Prevalence estimates for celiac disease (CD) depend on the method used. The role of deamidated gliadin peptide (DGP) and genetic testing in epidemiological studies and diagnostic settings of celiac disease (CD) has still to be established. Objectives: The objective of this article is to assess the prevalence of CD in Latvia by combining serological tests with DQ2.5/ DQ8 testing. Methods: A total of 1444 adults from a randomly selected cross-sectional general population sample were tested by ELISA for tTG IgA, DGP IgA and IgG antibodies (QUANTA Lite, Inova Diagnostics Inc). Samples with tTG IgA 20U were tested for EMA IgA by indirect immunofluorescence assay, and all specimens wi…

medicine.medical_specialty:MEDICINE [Research Subject Categories]Tissue transglutaminasePopulationSerologyChemiluminescent assaysEpidemiologyGenotypePrevalenceCeliac diseaseMedicineDQ2.5/8 genotypeeducationGenotypingGenetic testingeducation.field_of_studyDeamidated gliadin peptidemedicine.diagnostic_testbiologybusiness.industryTissue transglutaminaseGastroenterologynutritional and metabolic diseasesOriginal ArticlesOncologyImmunologybiology.proteinAntibodybusinessUnited European Gastroenterology Journal
researchProduct

Optimizing the use of linaclotide in patients with constipation-predominant irritable bowel syndrome : an expert consensus report

2017

INTRODUCTION: Irritable bowel syndrome (IBS) is a functional bowel disorder characterized by chronic or recurrent abdominal pain in association with defecation or a change in bowel habits. A predominant disorder of bowel habits, IBS is classified into three main subtypes: constipation-predominant IBS (IBS-C), diarrhea-predominant IBS (IBS-D) and IBS alternating between constipation and diarrhea (IBS-M). Linaclotide is a first-in-class, oral, once-daily guanylate cyclase-C receptor agonist (GC-CA) that is licensed for the symptomatic treatment of moderate-to-severe IBS-C in adults. This review aims to facilitate and optimize clinical practices, establishing common guidelines to monitor patie…

medicine.medical_specialtyAbdominal painAbdominal painConstipationReviewRecommendationsGastroenterologyIrritable Bowel Syndrome03 medical and health scienceschemistry.chemical_compound0302 clinical medicineBloatingGastrointestinal AgentsInternal medicinemedicineHumansPharmacology (medical)030212 general & internal medicineLinaclotideGastroenterologiaIrritable bowel syndromeMedicine(all)business.industryBloatingGastroenterologyIntestins -- MalaltiesGeneral Medicinemedicine.diseaseSíndrome do Intestino IrritávelRheumatologyDiarrheaTreatment OutcomechemistryDefecationLinaclotide030211 gastroenterology & hepatologyPatient managementmedicine.symptomConstipation-predominant irritable bowel syndromebusinessPeptidesReceptors Atrial Natriuretic FactorConstipation
researchProduct

Adrenergic modulation of astroglial phospholipase D activity and cell proliferation.

1999

As phospholipase D (PLD) activation has been associated with mitogenic signalling in several cell types, we tested an association between adrenergic activation of PLD and cellular proliferation in primary cultures of rat cortical astrocytes. In 2-week old cultures, PLD activation by noradrenaline (EC50: 0.49 microM) was inhibited by prazosin, a specific antagonist at alpha1-adrenergic receptors (IC50: 0.23 microM). Adrenergic PLD activation was not affected by genistein, an inhibitor of tyrosine kinases, or by Ro 31-8220, an inhibitor of protein kinase C (PKC), but was dose-dependently depressed in the presence of brefeldin A (1-100 microg/ml), an inhibitor of ARF activation. In experiments…

medicine.medical_specialtyAdrenergic AntagonistsAdrenergicBiologyPharmacologychemistry.chemical_compoundNorepinephrineGTP-Binding ProteinsIsoprenalineInternal medicinemedicineAdrenergic antagonistPrazosinPhospholipase DPhospholipase D activityAnimalsMolecular BiologyProtein kinase CCells CulturedBrefeldin APhospholipase DGeneral NeurosciencePrazosinBrefeldin AAdrenergic AgonistsPropranololRatsReceptors AdrenergicEndocrinologychemistryAlcoholsAstrocyteslipids (amino acids peptides and proteins)Neurology (clinical)Cell DivisionDevelopmental Biologymedicine.drugSignal TransductionBrain research
researchProduct

Glutamatergic activation of hippocampal phospholipase D: postnatal fading and receptor desensitization.

2002

Abstract: Phospholipase D (PLD) activity was determined in rat hippocampal slices between postnatal days 3 and 35. After birth, basal PLD activity was low and, within 2 weeks, increased to reach a plateau that was maintained up to the adult age. Likewise the response to glutamate developed postnatally to reach a maximum at day 8, but then faded rapidly and was almost absent at day 35. Activation of PLD by 4β-phorbol 12β,13α-dibutyrate (PDB) was independent of age, whereas the effect of aluminum fluoride (AlF4−) increased to a plateau within the first week. At day 8, PLD stimulation by glutamate via metabotropic receptors involved protein kinase C activation, but was independent of Ca2+ infl…

medicine.medical_specialtyAgingGlutamic AcidStimulationBiologyHippocampal formationIn Vitro TechniquesReceptors Metabotropic GlutamateBiochemistryHippocampusCellular and Molecular NeuroscienceGlutamatergicchemistry.chemical_compoundInternal medicinemedicinePhospholipase DCholineAnimalsRats WistarPhospholipase DGlutamate receptorRatsEnzyme Activationenzymes and coenzymes (carbohydrates)Metabotropic receptorEndocrinologychemistryAnimals NewbornMetabotropic glutamate receptorlipids (amino acids peptides and proteins)Journal of neurochemistry
researchProduct

The metabolism and availability of essential fatty acids in animal and human tissues.

1994

Essential fatty acids (EFA), which are not synthesized in animal and human tissues, belong to the n-6 and n-3 families of polyunsaturated fatty acids (PUFA), derived from linoleic acid (LA, 18:2n-6) and alpha-linolenic acid (LNA, 18:3n-3). Optimal requirements are 3-6% of ingested energy for LA and 0.5-1% for LNA in adults. Requirements in LNA are higher in development. Dietary sources of LA and LNA are principally plants, while arachidonic acid (AA, 20:4n-6) is found in products from terrestrian animals, and eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are found in products from marine animals. EFA are principally present in dietary triacylglycerols, which should be hydrolyze…

medicine.medical_specialtyAgingLinolenic acidLinoleic acidBiological AvailabilityBiologyIntestinal absorptionchemistry.chemical_compoundInternal medicine[SDV.BDD] Life Sciences [q-bio]/Development BiologymedicineAnimalsHumansNutritional Physiological Phenomena[SDV.BDLR] Life Sciences [q-bio]/Reproductive Biologychemistry.chemical_classificationFatty Acids EssentialNutritional Requirementsfood and beveragesMetabolismEicosapentaenoic acidDietary FatsHormones[SDV.AEN] Life Sciences [q-bio]/Food and NutritionEndocrinologyBiochemistrychemistryIntestinal AbsorptionDocosahexaenoic acidOrgan Specificitylipids (amino acids peptides and proteins)Arachidonic acidDigestionPolyunsaturated fatty acidReproduction, nutrition, development
researchProduct